Bevacizumab is a class of anti-VEGF monoclonal antibodies used in tumor immunotherapy that was prone to acquired drug resistance.32 When combined with capecitabine, the drug resistance of monotherapy was reversed.33 In the gSig4 subtype, bevacizumab and capecitabine had the fewest samples with disease progression after treatment, further suggesting that the metabolic subtype is a reliable and independent prognostic indicator. The gene discussed is VEGFA; the disease is neoplasm.